(Q48142535)

9 February 2018

title

Adrenal suppression secondary to inhaled fluticasone propionate (English)

1 reference

9 February 2018

author name string

Taylor AV

1

1 reference

9 February 2018

Laoprasert N

2

1 reference

9 February 2018

Zimmerman D

3

1 reference

9 February 2018

Sachs MI

4

1 reference

9 February 2018

publication date

1 July 1999

1 reference

9 February 2018

Annals of Allergy, Asthma & Immunology

published in

1 reference

9 February 2018

volume

83

1 reference

9 February 2018

issue

1

1 reference

9 February 2018

page(s)

68-70

1 reference

9 February 2018

Inhaled glucocorticoids for asthma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963515-6

7 January 2021

Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963515-6

7 January 2021

Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963515-6

7 January 2021

Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963515-6

7 January 2021

Choosing a long-term controller medication in childhood asthma. The proverbial two-edged sword

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963515-6

7 January 2021

Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963515-6

7 January 2021

Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963515-6

7 January 2021

Inhaled corticosteroids: benefits and risks

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963515-6

7 January 2021

Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963515-6

7 January 2021

A placebo controlled trial of fluticasone propionate in asthmatic children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963515-6

7 January 2021

Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963515-6

7 January 2021

10.1016/S1081-1206(10)63515-6

Identifiers

DOI

1 reference

9 February 2018

1 reference

9 February 2018